YOUR SEARCH FOR Text 61 RESULTS
11 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… 2023 – Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. … on eight programs that have high potential value for us and discontinued six other …
12 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended December … GAAP loss on change in fair value of acquisition-related contingent …
13 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… pipeline. Opzelura has now become the market share leader among branded agents for new atopic … GAAP loss on change in fair value of acquisition-related contingent …
14 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… mg/kg administered every two weeks. We plan to share the full dataset at a future medical … GAAP loss on change in fair value of acquisition-related contingent …
15 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… endpoint Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. … data from these studies are anticipated to be shared in the fourth quarter of 2023. The Phase …
16 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Incyte through its next phase of growth and value creation for patients, partners and shareholders. Our second quarter results reflect …
17 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… Highlights (unaudited, in thousands, except per share amounts) … 652,604 460,363 42% GAAP change in fair value of acquisition-related contingent …
18 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended September … GAAP loss (gain) on change in fair value of acquisition-related contingent …
19 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… second half of 2025. In December 2024 , Incyte shared additional data from its BET inhibitor … GAAP (gain) loss on change in fair value of acquisition-related contingent …
20 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… Highlights (unaudited, in thousands, except per share amounts) Three Months Ended December … GAAP (gain) loss on change in fair value of acquisition-related contingent …